Published in J Immunol on November 01, 1985
T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Proc Natl Acad Sci U S A (1990) 6.19
Experimental autoimmune encephalomyelitis induction in genetically B cell-deficient mice. J Exp Med (1996) 3.36
The CD28 ligand B7/BB1 provides costimulatory signal for alloactivation of CD4+ T cells. J Exp Med (1991) 3.35
In vivo induction of anergy in peripheral V beta 8+ T cells by staphylococcal enterotoxin B. J Exp Med (1990) 2.69
Induction of autoreactive B cells allows priming of autoreactive T cells. J Exp Med (1991) 2.60
Successful T cell priming in B cell-deficient mice. J Exp Med (1995) 2.52
T helper cell subsets require the expression of distinct costimulatory signals by antigen-presenting cells. Proc Natl Acad Sci U S A (1988) 2.21
Distinct features of dendritic cells and anti-Ig activated B cells as stimulators of the primary mixed leukocyte reaction. J Exp Med (1989) 2.00
B lymphocytes in vivo fail to prime naive T cells but can stimulate antigen-experienced T lymphocytes. J Exp Med (1993) 1.84
Tolerogenicity of resting and activated B cells. J Exp Med (1994) 1.25
Altered I-A protein-mediated transmembrane signaling in B cells that express truncated I-Ak protein. Proc Natl Acad Sci U S A (1989) 1.21
B cells are not essential for peripheral T-cell tolerance. Proc Natl Acad Sci U S A (1996) 1.15
Anti-CD45RB/anti-TIM-1-induced tolerance requires regulatory B cells. Am J Transplant (2012) 1.10
Follicular dendritic cells help resting B cells to become effective antigen-presenting cells: induction of B7/BB1 and upregulation of major histocompatibility complex class II molecules. J Exp Med (1993) 1.09
B cell antigen presentation in the initiation of follicular helper T cell and germinal center differentiation. J Immunol (2014) 1.07
Mixed isotype class II antigen expression. A novel class II molecule is expressed on a murine B cell lymphoma. J Exp Med (1989) 0.96
Alloantigen presentation by B cells: analysis of the requirement for B-cell activation. Immunology (1995) 0.90
PARP-1 deficiency increases the severity of disease in a mouse model of multiple sclerosis. J Biol Chem (2009) 0.87
Potential impact of B cells on T cell function in multiple sclerosis. Mult Scler Int (2011) 0.85
Antigen presentation by liposomes bearing class II MHC and membrane IL-1. Yale J Biol Med (1990) 0.85
Specific antigen targeting to surface IgE and IgG on mouse bone marrow-derived mast cells enhances efficiency of antigen presentation. Immunology (1998) 0.79
Induction of T-cell hyporesponsiveness by intrahepatic modulation of donor antigen-presenting cells. Immunology (1995) 0.77
Effects of Cyanobacteria Oscillatoria sp. Lipopolysaccharide on B Cell Activation and Toll-like receptor 4 signaling. Toxicol Lett (2017) 0.77
Immunoglobulins on the surface of lymphocytes. I. Distribution and quantitation. J Exp Med (1971) 8.22
Immunoglobulins on the surface of lymphocytes. II. The bone marrow as the main source of lymphocytes with detectable surface-bound immunoglobulin. J Exp Med (1971) 5.43
The relation between major histocompatibility complex (MHC) restriction and the capacity of Ia to bind immunogenic peptides. Science (1987) 5.32
Combined studies of complement receptor and surface immunoglobulin-bearing cells and sheep erythrocyte rosette-forming cells in normal and leukemic human lymphocytes. J Clin Invest (1973) 5.31
Immunoglobulins on the surface of lymphocytes. IV. Distribution in hypogammaglobulinemia, cellular immune deficiency, and chronic lymphatic leukemia. J Clin Invest (1971) 4.98
Isolation and characterization of antigen-Ia complexes involved in T cell recognition. Cell (1986) 4.71
Two different complement receptors on human lymphocytes. One specific for C3b and one specific for C3b inactivator-cleaved C3b. J Exp Med (1973) 4.46
The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J Immunol (1994) 4.37
The minimal number of class II MHC-antigen complexes needed for T cell activation. Science (1990) 4.09
Several common HLA-DR types share largely overlapping peptide binding repertoires. J Immunol (1998) 3.95
Prominent role of secondary anchor residues in peptide binding to HLA-A2.1 molecules. Cell (1993) 3.80
Antigen recognition by H-2-restricted T cells. II. A tryptic ovalbumin peptide that substitutes for processed antigen. J Immunol (1984) 3.72
Structural characteristics of an antigen required for its interaction with Ia and recognition by T cells. Nature (1987) 3.63
Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science (1992) 3.39
Studies on the capacity of B cells to serve as antigen-presenting cells. J Immunol (1981) 3.38
Antigen analog-major histocompatibility complexes act as antagonists of the T cell receptor. Cell (1992) 3.24
Receptors for aggregated IgG on mouse lymphocytes: their presence on thymocytes, thymus-derived, and bone marrow-derived lymphocytes. J Exp Med (1974) 3.21
Structure and function of immunoglobulin A. Prog Allergy (1972) 3.14
Antigen presentation by normal B cells, B cell tumors, and macrophages: functional and biochemical comparison. J Immunol (1982) 3.08
Receptors for IgG: subclass specificity of receptors on different mouse cell types and the definition of two distinct receptors on a macrophage cell line. J Exp Med (1977) 2.98
A subclass of human gamma-A-globulins (gamma-A2) which lacks the disulfied bonds linking heavy and light chains. J Exp Med (1968) 2.98
The reaction of monomeric and aggregated immunoglobulins with C1. Immunochemistry (1971) 2.96
Prediction of major histocompatibility complex binding regions of protein antigens by sequence pattern analysis. Proc Natl Acad Sci U S A (1989) 2.73
The small subunit of HL-A antigens is beta 2-microglobulin. J Exp Med (1973) 2.68
Immunological self, nonself discrimination. Science (1987) 2.59
Interaction between a "processed" ovalbumin peptide and Ia molecules. Proc Natl Acad Sci U S A (1986) 2.42
Protein A reactivity with mouse immunoglobulins. Structural relationship between some mouse and human immunoglobulins. J Immunol (1970) 2.38
Thymus-derived (T) cell immunoglobulins. Presence of a receptor site for IgG and absence of large amounts of "buried" Ig determinants on T cells. J Exp Med (1972) 2.35
Immunoglobulins on the surface of lymphocytes. 3. Bursal origin of surface immunoglobulins on chicken lymphocytes. J Immunol (1971) 2.33
Analysis of the HLA-restricted influenza-specific cytotoxic T lymphocyte response in transgenic mice carrying a chimeric human-mouse class I major histocompatibility complex. J Exp Med (1991) 2.33
Identification of Db- and Kb-restricted subdominant cytotoxic T-cell responses in lymphocytic choriomeningitis virus-infected mice. Virology (1998) 2.31
A new mouse immunoglobulin: IgG3. J Exp Med (1971) 2.27
Requirements for the processing of antigens by antigen-presenting B cells. I. Functional comparison of B cell tumors and macrophages. J Immunol (1982) 2.25
The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev (1987) 2.24
Analysis of cytotoxic T cell responses to dominant and subdominant epitopes during acute and chronic lymphocytic choriomeningitis virus infection. J Immunol (1996) 2.24
Cryoimmunoglobulins. Semin Hematol (1973) 2.18
Definition of specific peptide motifs for four major HLA-A alleles. J Immunol (1994) 2.11
Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol (1994) 2.07
Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. J Immunol (1995) 2.05
Glatiramer acetate (Copaxone) induces degenerate, Th2-polarized immune responses in patients with multiple sclerosis. J Clin Invest (2000) 2.00
B cells as antigen-presenting cells: the requirement for B cell activation. J Immunol (1983) 1.93
Autologous peptides constitutively occupy the antigen binding site on Ia. Science (1988) 1.92
Structural analysis of peptides capable of binding to more than one Ia antigen. J Immunol (1989) 1.85
Degenerate cytotoxic T cell epitopes from P. falciparum restricted by multiple HLA-A and HLA-B supertype alleles. Immunity (1997) 1.84
Human memory CTL response specific for influenza A virus is broad and multispecific. Hum Immunol (2000) 1.84
Studies on receptors for IgG on epithelial cells of the rat intestine. J Immunol (1977) 1.82
Peptide binding to the most frequent HLA-A class I alleles measured by quantitative molecular binding assays. Mol Immunol (1994) 1.80
Immunological identity of the small subunit of HL-A antigens and beta2-microglobulin and its turnover on the cell membrane. Proc Natl Acad Sci U S A (1974) 1.80
Practical, biochemical and evolutionary implications of the discovery of HLA class I supermotifs. Immunol Today (1996) 1.79
Sharing of individual antigenic determinants between a gamma G and a gamma M protein in the same myeloma serum. Proc Soc Exp Biol Med (1970) 1.79
Studies on the structure of mouse gamma-A myeloma proteins. Biochemistry (1968) 1.78
HLA DR4w4-binding motifs illustrate the biochemical basis of degeneracy and specificity in peptide-DR interactions. J Immunol (1993) 1.78
Development of a lipopeptide-based therapeutic vaccine to treat chronic HBV infection. I. Induction of a primary cytotoxic T lymphocyte response in humans. J Clin Invest (1995) 1.78
Single amino acid changes in DR and antigen define residues critical for peptide-MHC binding and T cell recognition. J Immunol (1991) 1.75
Antigen analogs/MHC complexes as specific T cell receptor antagonists. Annu Rev Immunol (1994) 1.73
Human monoclonal gamma G-cryoglobulins with anti-gamma-globulin activity. J Clin Invest (1968) 1.72
Antigen recognition by T cells and B cells: recognition of cross-reactivity between native and denatured forms of globular antigens. Clin Immunol Immunopathol (1980) 1.72
Catabolism of human gammaG-immunoglobulins of different heavy chain subclasses. I. Catabolism of gammaG-myeloma proteins in man. J Clin Invest (1968) 1.71
MHC interaction and T cell recognition of carbohydrates and glycopeptides. J Immunol (1992) 1.71
Specificity of recombination of H and L chains from human gamma-G-myeloma proteins. J Exp Med (1965) 1.69
Structural studies of human gamma D myeloma protein. Biochemistry (1970) 1.66
In vitro evidence that Langerhans cells can adopt two functionally distinct forms capable of antigen presentation to T lymphocytes. J Immunol (1989) 1.63
Capacity of intact proteins to bind to MHC class II molecules. J Immunol (1989) 1.63
Immunodominance analysis of CTL responses to influenza PR8 virus reveals two new dominant and subdominant Kb-restricted epitopes. J Immunol (1996) 1.61
I-Ad-binding peptides derived from unrelated protein antigens share a common structural motif. J Immunol (1988) 1.61
Measurement of MHC/peptide interactions by gel filtration. Curr Protoc Immunol (2001) 1.60
Induction of anti-tumor cytotoxic T lymphocytes in normal humans using primary cultures and synthetic peptide epitopes. Proc Natl Acad Sci U S A (1994) 1.56
IgD: a major immunoglobulin on the surface of lymphocytes from patients with chronic lymphatic leukemia. J Immunol (1974) 1.56
The cytophilic activity of human immunoglobulins. J Immunol (1970) 1.55
Mitogen activation of human chronic lymphatic leukemia cells. I. Synthesis and secretion of immunoglobulin. J Immunol (1977) 1.52
Definition of an HLA-A3-like supermotif demonstrates the overlapping peptide-binding repertoires of common HLA molecules. Hum Immunol (1996) 1.52
Interaction of an immunodominant epitope with Ia molecules in T-cell activation. Proc Natl Acad Sci U S A (1988) 1.51
Human histocompatibility leukocyte antigen-binding supermotifs predict broadly cross-reactive cytotoxic T lymphocyte responses in patients with acute hepatitis. J Clin Invest (1997) 1.50
Heavy-chain subclasses of human gamma-G-globulin. Peptide and immunochemical relationships. Biochemistry (1967) 1.50
The carbohydrate contents of fragments and polypeptide chains of human gamma-G-myeloma proteins of different heavy-chain subclasses. Biochemistry (1968) 1.49
Comparison of effects of transforming growth factor-beta and cyclosporin A on antigen-presenting cells of blood and epidermis. J Invest Dermatol (1991) 1.48
Requirements for the processing of antigen by antigen-presenting B cells. II. Biochemical comparison of the fate of antigen in B cell tumors and macrophages. J Immunol (1982) 1.48
Effect of pH on MHC class II-peptide interactions. J Immunol (1992) 1.46
Characterization of a naturally processed MHC class II-restricted T-cell determinant of hen egg lysozyme. Nature (1989) 1.46
Recombination of heavy and light chains of human gamma-a-myeloma proteins: formation of hybrid molecules and configurational specificity. J Exp Med (1966) 1.45
Regulation of catabolism of IgM heavy chains in a B lymphoma cell line. J Biol Chem (1982) 1.44
Characterization of the specificity of peptide binding to four DR haplotypes. J Immunol (1990) 1.43
Utilization of MHC class I transgenic mice for development of minigene DNA vaccines encoding multiple HLA-restricted CTL epitopes. J Immunol (1999) 1.41
Capacity of B cells to function as stimulators of a primary mixed leukocyte reaction. J Immunol (1986) 1.40
Immunological memory: contribution of memory B cells expressing costimulatory molecules in the resting state. J Immunol (2001) 1.39
Antigen presentation to T cell hybridomas by a macrophage cell line: an inducible function. J Immunol (1982) 1.37
mu-Chains from a nonsecretor B cell line differ from secreted mu-chains at the C-terminal end. J Immunol (1978) 1.36